Scheduled injection of ramosetron for prevention of nausea and vomiting following single-port access total laparoscopic hysterectomy: a prospective randomized study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
ObjectiveThe purpose of this study was to evaluate the effectiveness of scheduled ramosetron injections for controllingpostoperative nausea and vomiting (PONV) after single-port access total laparoscopic hysterectomy (SPA-TLH). MethodsNinety patients who underwent SPA-TLH at the Korean National Health Insurance Service Ilsan Hospital between June2013 and July 2014 were enrolled in this prospective, randomized, double-blinded, placebo-controlled study. Thepatients were divided into 2 groups as follows: the ramosetron group (0.3 mg intravenously [IV]; n=45) and the placebogroup (normal saline IV; n=45). Both groups received their respective injections 12 and 24 hours post surgery. Theincidence and severity of PONV (numerical rating scale, 0–10), and the use of rescue antiemetics post surgery wereevaluated. ResultsDemographic and perioperative statistically significant differences were not observed between the 2 groups. Theincidence of PONV in the ramosetron and placebo groups was 46.7% and 51.1%, respectively (P=0.51). We foundsignificant differences in the severity of PONV between the 24- to 48-hour postoperative periods in both groups(ramosetron group, P=0.04 and placebo group, P=0.03). The use of rescue antiemetics was significantly lower in theramosetron group than in the placebo group (P=0.02). ConclusionAfter general anesthesia, scheduled injections of ramosetron 12 and 24 hours after SPA-TLH reduced the severity ofPONV and the use of rescue antiemetics. Administration of ramosetron can be considered not only immediately afterSPA-TLH but also during the first 24-hour recovery period. Trial RegistrationClinicalTrials.gov Identifier: NCT 02011659
Abstract
ObjectiveThe purpose of this study was to evaluate the effectiveness of scheduled ramosetron injections for controllingpostoperative nausea and vomiting (PONV) after single-port access total laparoscopic hysterectomy (SPA-TLH). MethodsNinety patients who underwent SPA-TLH at the Korean National Health Insurance Service Ilsan Hospital between June2013 and July 2014 were enrolled in this prospective, randomized, double-blinded, placebo-controlled study. Thepatients were divided into 2 groups as follows: the ramosetron group (0.3 mg intravenously [IV]; n=45) and the placebogroup (normal saline IV; n=45). Both groups received their respective injections 12 and 24 hours post surgery. Theincidence and severity of PONV (numerical rating scale, 0–10), and the use of rescue antiemetics post surgery wereevaluated. ResultsDemographic and perioperative statistically significant differences were not observed between the 2 groups. Theincidence of PONV in the ramosetron and placebo groups was 46.7% and 51.1%, respectively (P=0.51). We foundsignificant differences in the severity of PONV between the 24- to 48-hour postoperative periods in both groups(ramosetron group, P=0.04 and placebo group, P=0.03). The use of rescue antiemetics was significantly lower in theramosetron group than in the placebo group (P=0.02). ConclusionAfter general anesthesia, scheduled injections of ramosetron 12 and 24 hours after SPA-TLH reduced the severity ofPONV and the use of rescue antiemetics. Administration of ramosetron can be considered not only immediately afterSPA-TLH but also during the first 24-hour recovery period. Trial RegistrationClinicalTrials.gov Identifier: NCT 02011659
참고문헌 (24)
- Macario A, "Which clinical anesthesia outcomes are important to avoid? The perspective of patients", Anesth Analg, 89, pp.652~658 (1999)
- Gan TJ, "Consensus guidelines for managing postoperative nausea and vomiting", Anesth Analg, 97, pp.62~71 (2003)
- Rowbotham D, "Recognising risk factors", Nurs Times, 91, pp.44~46 (1995)
- Stadler M, "Difference in risk factors for postoperative nausea and vomiting", Anesthesiology, 98, pp.46~52 (2003)
- Jacobson TZ, "Safe laparoscopy : is it possible", Curr Opin Obstet Gynecol, 16, pp.283~288 (2004)
- Korolija D, "Evaluation of quality of life after laparoscopic surgery : evidence-based guidelines of the European Association for Endoscopic Surgery", Surg Endosc, 18, pp.879~897 (2004)
- Kim TJ, "Single-port-access laparoscopic-assisted vaginal hysterectomy versus conventional laparoscopic-assisted vaginal hysterectomy: a comparison of perioperative outcomes", Surg Endosc, 24, pp.2248~2252 (2010)
- Song T, "Cosmetic outcomes of laparoendoscopic singlesite hysterectomy compared with multi-port surgery : randomized controlled trial", J Minim Invasive Gynecol, 20, pp.460~467 (2013)
- Watcha MF, "Postoperative nausea and vomiting. Its etiology, treatment, and prevention", Anesthesiology, 77, pp.162~184 (1992)
- Fijihara A, "Ramosetron hydrochloride : affinity for cloned human 5-HT3 receptor antagonistic and anti-emetic effect in ferret", Clin Rep, 30, pp.1955~1964 (1996)
- Lee D, "The effect of oral and IV ramosetron on postoperative nausea and vomiting in patients undergoing gynecological laparoscopy with total intravenous anesthesia", J Anesth, 23, pp.46~50 (2009)
- 이선열, "부인과 복강경 수술 환자에서 Ramosetron의 투여 시기가 수술 후 오심과 구토에 미치는 영향", Korean Journal of Anesthesiology, 56(6), pp.663~668 (2009), 대한마취통증의학회
- Yim GW, "Transumbilical single-port access versus conventional total laparoscopic hysterectomy: surgical outcomes", Am J Obstet Gynecol, 203, pp.26~ (2010)
- 김성희, "Postoperative outcomes of natural orifice transluminal endoscopic surgery-assisted vaginal hysterectomy and conventional laparoscopic-assisted vaginal hysterectomy: a comparative study", Obstetrics & Gynecology Science, 61(2), pp.261~266 (2018), 대한산부인과학회[DOI]
- Gan TJ, "Postoperative nausea and vomiting--can it be eliminated", JAMA, 287, pp.1233~1236 (2002)
- Apfel CC, "A simplified risk score for predicting postoperative nausea and vomiting : conclusions from cross-validations between two centers", Anesthesiology, 91, pp.693~700 (1999)
- Gan TJ, "Risk factors for postoperative nausea and vomiting", Anesth Analg, 102, pp.1884~1898 (2006)
- Ali SZ, "Effect of supplemental pre-operative fluid on postoperative nausea and vomiting", Anaesthesia, 58, pp.780~784 (2003)
- Kim SI, "Comparison of ramosetron with ondansetron for prevention of postoperative nausea and vomiting in patients undergoing gynaecological surgery", Br J Anaesth, 103, pp.549~553 (2009)
- Mihara T, "Reevaluation of the effectiveness of ramosetron for preventing postoperative nausea and vomiting : a systematic review and meta-analysis", Anesth Analg, 117, pp.329~339 (2013)
- 김민수, "Efficacy of Palonosetron vs. Ramosetron for the Prevention of Postoperative Nausea and Vomiting: A Meta-Analysis of Randomized Controlled Trials", Yonsei Medical Journal, 58(4), pp.848~858 (2017), 연세대학교의과대학[DOI]
- Tang J, "The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost-benefit as a prophylactic antiemetic in the ambulatory setting", Anesth Analg, 86, pp.274~282 (1998)
- Sun R, "The effect of timing of ondansetron administration in outpatients undergoing otolaryngologic surgery", Anesth Analg, 84, pp.331~336 (1997)
- Cruz NI, "Timing of ondansetron administration to prevent postoperative nausea and vomiting", P R Health Sci J, 27, pp.43~47 (2008)